I like biotech, but worry about the high risk of betting on pipeline drugs. AFFX makes the genetic chips and equipment used by a high proportion of biotech researchers. Attractive price currently.

Small cap with solid WiMax products. May get swamped by bigger players (or bought) at some point, but seems to be growing its market in global niches.

Bought a year ago, a Magic Formula pick. Like ARB particularly because of its upside growth potential from two new developments, the People Meter system of measuring radio listeners, and the Apollo Project, a breakthrough strategy for market research. As these two new products come on line, ARB's top line should grow fast. At this point it appears that most of the resistance to People Meter (Clear Channel has been fighting it) appears to have died down, and the rollout should begin to gather steam. Know less about Apollo rollout plans.

A solid company that was on the Magic Formula list a year ago.

Another Magic Formula pick. This one in a troubled industry, but HW has excellent prospects for its construction materials and exciting opportunities in both nanotech and synthetic fuels (coal to gas) that are likely to deliver good returns for year.

What's not to like. A consistently excellent performer.

Great global brand with solid growth prospects.

Stock has slid back some of late and is likely to be somewhat volatile, but this company is far from the end of its growth cycle.